Novo Nordisk A/S (NYSE:NVO) has been given a consensus recommendation of “Buy” by the eight research firms that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company.

Several research analysts have issued reports on the company. Zacks Investment Research cut Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Thursday, June 7th. Sanford C. Bernstein raised Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Monday, July 2nd.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in Novo Nordisk A/S by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 27,685 shares of the company’s stock worth $1,485,000 after purchasing an additional 1,070 shares in the last quarter. Oxbow Advisors LLC grew its position in Novo Nordisk A/S by 3.8% during the 1st quarter. Oxbow Advisors LLC now owns 32,296 shares of the company’s stock worth $1,591,000 after purchasing an additional 1,190 shares in the last quarter. Wedbush Securities Inc. grew its position in Novo Nordisk A/S by 3.3% during the 2nd quarter. Wedbush Securities Inc. now owns 39,181 shares of the company’s stock worth $1,807,000 after purchasing an additional 1,253 shares in the last quarter. HighVista Strategies LLC grew its position in Novo Nordisk A/S by 4.1% during the 1st quarter. HighVista Strategies LLC now owns 32,700 shares of the company’s stock worth $1,610,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Boston Common Asset Management LLC grew its position in Novo Nordisk A/S by 0.9% during the 2nd quarter. Boston Common Asset Management LLC now owns 149,793 shares of the company’s stock worth $6,908,000 after purchasing an additional 1,391 shares in the last quarter. 6.73% of the stock is currently owned by institutional investors.

NYSE NVO opened at $46.87 on Friday. The firm has a market capitalization of $115.11 billion, a price-to-earnings ratio of 20.03, a P/E/G ratio of 2.48 and a beta of 0.66. Novo Nordisk A/S has a 1 year low of $44.28 and a 1 year high of $58.37.

The business also recently declared a special dividend, which will be paid on Tuesday, August 28th. Shareholders of record on Monday, August 20th will be issued a $0.4669 dividend. The ex-dividend date of this dividend is Friday, August 17th. This represents a dividend yield of 1.72%. Novo Nordisk A/S’s dividend payout ratio is currently 38.89%.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.

Recommended Story: Marijuana Stocks

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.